A Prescription Drug User Fee Act target date of November 30, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application ...
A Kura Oncology and Kyowa Kirin-partnered drug vying to become the first FDA-approved treatment for cases of acute myeloid leukemia (AML) carrying a particular genetic signature will have its ...
Revuforj, a menin inhibitor, is under priority review for relapsed or refractory mutant NPM1 AML, with a target action date of October 25, 2025. The AUGMENT-101 trial demonstrated Revuforj's efficacy, ...
CERo Therapeutics received FDA approval for its IND CMC amendment, crucial for starting CER-1236 patient dosing. The phase 1 trial will assess CER-1236's safety and efficacy in relapsed or refractory ...
Anthracycline and cytarabine chemotherapy has been the backbone of induction chemotherapy for AML for more than 50 years. Advances in our understanding of leukemia biology and the development of ...
Chemoinduction therapy and its response in Jehovah’s Witnesses with acute lymphoblastic leukemia: A systematic review. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results